Survodutide (BI 456906) is a dual GLP-1 and glucagon receptor agonist in Phase 3 trials for obesity and MASH (metabolic-associated steatohepatitis), demonstrating approximately 14.9% weight loss at 46 weeks in Phase 2b studies.
GLP-1/Glucagon Dual Agonist
Survodutide (BI 456906) is a dual GLP-1 and glucagon receptor agonist in Phase 3 trials for obesity and MASH (metabolic-associated steatohepatitis), demonstrating approximately 14.9% weight loss at 46 weeks in Phase 2b studies.
Research Use Only — not intended for human consumption
Research peptides are sold for laboratory use only and are not intended for human consumption.
Week-by-week dosing, reconstitution steps, supplies checklist, and cycle tips.
Week-by-week dosing protocol1 clinic in our directory offer Survodutide. Use the button below to find one near you.
Find a Peptide Clinic Near YouArticles about Survodutide and related topics
Peptide Sciences, the largest grey-market research peptide vendor in the US, voluntarily shut down on March 6, 2026. Here is what happened, why it closed, and what the closure means for researchers and the broader peptide industry.
Looking for where to buy retatrutide for research use? Here’s a supplier checklist (COAs, testing, reviews, red flags) plus the clinical-trial pathway for legitimate access.
The injectable peptides craze is sweeping the US, with many individuals experimenting for various health benefits. Learn the key facts and implications for patients.
MyPeptideMatch.com does not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy. Regulatory status may change.